Table 2.
Retrospective observational studies comparing cefiderocol with colistin-based regimen in ICU patients with CRAB.
| Pascale et al. [32] Multicentre (January 2020–April 2021) |
Mazzitelli et al. [33] Single-Centre (August 2020–July 2022) |
Falcone et al. [10] Single-Centre (January 2020–August 2021) |
Russo et al. [11] Single-Centre (March 2020–August 2022) |
|
|---|---|---|---|---|
| Population: antibiotic-based regimen groups |
107 patients: 42 CFD 65 COL |
111 patients: 60 CFD 51 COL |
124 patients: 47 CFD 77 COL |
73 patients: 19 CFD 54 COL |
| COVID-19 coinfection | 100% | 32% | 38.7% | 100% |
| Site of infection | BSI (58%) LRTI (41%) Others (1%) |
BSI (47.7%) Pneumonia (52.3%) |
BSI (57.4%) VAP (25.5%) Others (17%) |
VAP and concomitant BSI (100%) |
| Patients received CFD in combination | 0 | 30 (50%) | 33 (70%) | 19 (100%) |
| Main agents co-administered with CFD | / | TGC (18/30) MEM (13/30) FOS (8/30) |
TGC (21/33) FOS (8/33) |
FOS (7/19) FOS + TGC (7/19) TGC (1/19) |
| 28–30 day all-cause mortality: CFD group vs. COL group |
23 (55%) vs. 38 (58%) (p-value: 0.7) |
26 (51%) vs. 22 (37%) (p-value: 0.13) |
16 (34%) vs. 43 (56%) (p-value: 0.018) |
6 (31.5%) vs. 53 (98%) (p-value < 0.001) |
Legend. ICU: intensive care unit; CRAB: carbapenem-resistant Acinetobacter baumannii; CFD: cefiderocol; COL: colistin; BSI: bloodstream infection; LRTI: low respiratory tract infection; VAP: ventilator-associated pneumonia; TGC: tigecycline; MEM: meropenem; FOS: fosfomycin.